RHYTHM Biosciences Ltd (RHY) - Total Liabilities

Latest as of December 2025: AU$955.41K AUD ≈ $676.01K USD

Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has total liabilities worth AU$955.41K AUD (≈ $676.01K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RHYTHM Biosciences Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

RHYTHM Biosciences Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how RHYTHM Biosciences Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see RHYTHM Biosciences Ltd assets under control.

RHYTHM Biosciences Ltd Competitors by Total Liabilities

The table below lists competitors of RHYTHM Biosciences Ltd ranked by their total liabilities.

Company Country Total Liabilities
ISA Holdings Ltd
JSE:ISA
South Africa ZAC38.72 Million
Lancashire Holdings Ltd
LSE:LRE
UK GBX3.04 Billion
Wanted Lab Inc.
KQ:376980
Korea ₩22.12 Billion
Leyand International Tbk
JK:LAPD
Indonesia Rp152.73 Billion
Cavendish Hydrogen ASA
OL:CAVEN
Norway Nkr12.70 Million
Wolftank Group AG
VI:WOLF
Austria €99.18 Million
Dunelm Group PLC
LSE:DNLM
UK GBX622.70 Million
Varopakorn Public Company Limited
BK:VARO
Thailand ฿886.04 Million

Liability Composition Analysis (2017–2025)

This chart breaks down RHYTHM Biosciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See RHYTHM Biosciences Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.31 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.45 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how RHYTHM Biosciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for RHYTHM Biosciences Ltd (2017–2025)

The table below shows the annual total liabilities of RHYTHM Biosciences Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-06-30 AU$2.17 Million
≈ $1.54 Million
+233.34%
2024-06-30 AU$651.54K
≈ $461.01K
-64.22%
2023-06-30 AU$1.82 Million
≈ $1.29 Million
+70.87%
2022-06-30 AU$1.07 Million
≈ $754.06K
-21.81%
2021-06-30 AU$1.36 Million
≈ $964.39K
+69.77%
2020-06-30 AU$802.85K
≈ $568.07K
+111.44%
2019-06-30 AU$379.71K
≈ $268.67K
+157.64%
2018-06-30 AU$147.38K
≈ $104.28K
+16.52%
2017-06-30 AU$126.48K
≈ $89.49K
--

About RHYTHM Biosciences Ltd

AU:RHY Australia Diagnostics & Research
Market Cap
$19.03 Million
AU$26.89 Million AUD
Market Cap Rank
#25366 Global
#1081 in Australia
Share Price
AU$0.08
Change (1 day)
+0.00%
52-Week Range
AU$0.08 - AU$0.26
All Time High
AU$2.00
About

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more